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segmental glomerulosclerosis (FSGS, 27%) and IgM nephropathy
(11%). Median age was 7.8 (Range 2.5 – 16.5) years with median
follow up post rituximab 33 (Range 1.5 to 87) months. Rituximab
was given as infusion at 375 mg / m2 . Each cycle constituted of
2 injections at an interval of 1-2 weeks followed by conﬁrmation of
B cell depletion. Single cycle achieved total B-cell depletion in all.
5 cases (all SRNS) received 2. Median duration for normalisation of
CD 19 was 4.65 (3 – 7) months. Among the SRNS, serum albumin
rose from mean 1.87 (SD  0.53) to 2.63 (SD  1.1) g/dl, (p¼0.06)
and UPCR fell from mean 19.3 (SD  12.04) to 9.8 (SD  10.96)
p¼ 0.15. 20% of SRNS (n¼2) achieved CR another 20% PR. Steroid
threshold among SDNS/FRNS fell from mean 0.47 (SD  0.19) to
0.17 (SD  0.23) mg/kg, p ¼0.0003 and dose of steroid at last follow
up fell men 0.88 (SD  0.56) to 0.22 (SD  0.43) mg/kg, p ¼0.0009.
50% of SDNS/FRNS (n¼11) did not have any relapse during the
follow up period and median time to ﬁrst relapse was 6.6 (Range 0.3
– 25) months.
Conclusions: Rituximab was demonstrated to be useful with sig-
niﬁcant beneﬁt particularly in the SDNS group.
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Introduction: Phospholipase A2 receptor 1 (PLA2R1) and throm-
bospondin type-1 domain-containing 7A (THSD7A) are podocyte
membrane proteins that have been identiﬁed as target antigens for
autoimmunity in membranous nephropathy (MN). The investiga-
tion of the pathogenicity of the involved autoantibodies has been
hampered by the fact that PLA2R1 is not expressed on rodent
podocytes. On the other hand, THSD7A is expressed on mouse
podocytes and shares over 90% of sequence homology with the
human protein. We have recently demonstrated that anti-THSD7A
antibodies isolated from a patient with THSD7A- associated MN can
cause morphological and clinical MN in mice, allowing further
investigations of disease pathogenesis. However, THSD7A-associ-
ated MN is a rare entity, incapacitating patient antibodies for larger
experimental procedures.
Methods: We generated polyclonal antibodies against human and
mouse THSD7A in rabbits using cDNA immunization. IgG from the
immunized rabbits and from preimmune control rabbits was af-
ﬁnity-puriﬁed and intravenously injected into mice. Urine was
collected daily and investigated for the development of proteinuria
by measurement of albumin-to-creatinine ratios. Mice were sacri-
ﬁced ﬁve, nine, and fourteen days after injection of rabbit IgG and
kidneys were analyzed using confocal and light microscopy.
Results: Puriﬁed IgG from immunized rabbits recognize, like pa-
tient autoantibodies, (a) conformation-dependent epitope(s) present
in both native human and mouse THSD7A in vitro. Moreover, two
hours after intravenous injection into mice, rabbit IgG is bound
along the glomerular ﬁltration barrier. Two days later, mice developS2proteinuria that rapidly increases and reaches around 10 g/g after
5 days and 200-300 g/g albumin-to-creatinine after 14 days with
some mice developing a severe nephrotic syndrome with ascites and
hyperlipidemia. In immunoﬂuorescent analysis, granular rabbit IgG
is found subepithelially along the glomerular ﬁltration barrier after
14 days and immunohistochemistry for rabbit IgG shows the classic
picture of human MN. Mice injected with puriﬁed IgG from rabbit
serum that was taken before THSD7A-immunization fail to develop
any of these changes.
Conclusions: Our study introduces a heterologous mouse model
that allows further mechanistic investigations of the molecular
events leading to membranous nephropathy.
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Introduction: The complement system can be activated via three
pathways, the classical (CP), alternative (AP) and lectin pathway
(LP). Studies have shown a role for complement in renal diseases
such as hemolytic uremic syndrome, C3 glomerulopathy and renal
transplantation. It is well known that heparin and some other
glycosaminoglycans (GAGs) inhibit complement activation. We
tested the pathway speciﬁc complement inhibiting potential of >70
GAGs. The results showed that some GAGs had a speciﬁc inhibitory
effect on the LP only. In this work we unravel the inhibitory
mechanism of GAGs on the LP.
Methods: GAGs were tested in the Wieslab complement screening
assay for a dose-dependent inhibition assay of the complement
pathways. Inhibition of ﬁcolin-3 mediated LP activation by GAGs
was tested in the Wieslab ﬁcolin-3 assay. To assess whether GAGs
inhibit the MBL – mannan interaction, GAGs were added to diluted
serum and incubated on mannan coated plates where after depo-
sition of MBL was measured. To test the inhibition of GAGs on
MASP activity, the GAGs were added to puriﬁed C4 and incubated
on MBL-MASP coated plates, C4 activation was measured by
detection of C4b. To assess whether the MBL-MASP complex binds
to heparin, serum was incubated on heparin-albumin coated plates
and binding of MBL, MASP-1 and MASP-2 was measured.
Results: In the Wieslab complement screening assay, (LMW-)hep-
arin dose-dependently inhibited all three pathways of complement.
Depolymerization of heparin followed by size-fractionation of the
resultant oligosaccharides revealed hexasaccharides and tetra-
saccharides to exclusively inhibit the LP, without any inhibition
potential for the CP and AP. Heparin (oligo’s) also show a dose-
dependent inhibition of the ﬁcolin-3 mediated LP activation,
however failed to inhibit the binding of MBL to mannan, indicating
inhibition by GAGs of MASP1/2 enzymes. This was proven in the
MASP-1/2 inhibition assays. Heparin (oligo’s) inhibited the C4
cleavage by MASP-1/2 in a dose-dependent way. Comparison of
deﬁned heparin-derived tetrasaccharides with various sulfation
revealed the fully N-, 2-O, 6-O-sulfated fragment the most potent
MASP-1/2 inhibitor. Vice versa the MBL-MASP complex showsKidney International Reports (2016) 1, S1–S22
